Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27748193 | 0.85 | P2RX7 (0.34) | TACR1SLC6A4KCNH2PDE2AGABRA2 | |
| SCHEMBL31170848 | 0.82 | RAD51 (0.38) | CYP3A4TSHRTACR1SLC6A4KCNH2 | |
| SCHEMBL29090166 | 0.82 | RAD51 (0.38) | CYP3A4TSHRTACR1SLC6A4KCNH2 | |
| SCHEMBL5635457 | 0.81 | GABRA2 (0.32) | CYP3A4TSHRTACR1SLC6A4KCNH2 | |
| SCHEMBL561772 | 0.79 | ALDH1A1 (0.40) | CYP3A4TSHRTACR1SLC6A4KCNH2 | |
| SCHEMBL12413780 | 0.78 | CYP3A4 (0.44) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL13822035 | 0.78 | CYP3A4 (0.58) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL24355384 | 0.77 | NOS3 (0.55) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL18711831 | 0.77 | CYP3A4 (0.43) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL31308541 | 0.74 | PDE2A (0.31) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420492-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | Ishihara Sangyo Kaisha, Ltd. (JP) | 2012-02-22 | — | — | EP | claimed |
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-09 | — | — | US | claimed |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| EP-3925962-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rakovina Therapeutics Inc. (CA) | 2021-12-22 | — | — | EP | disclosed |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | RAKOVINA THERAPEUTICS INC. (CA) | 2020-09-24 | — | — | US | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2420492-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | Ishihara Sangyo Kaisha, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | CYP3A4 626/4885CYP2D6 1470/4885TSHR 935/4885 |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | CYP3A4 3280/4885CYP2D6 3986/4885TSHR 4776/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | CYP3A4 3813/4885CYP2D6 4374/4885TSHR 654/4885 |
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | RDX, CYP4X1, BRIX1 | CYP3A4 171/4885CYP2D6 150/4885TSHR 307/4885 |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | CYP3A4 3232/4885CYP2D6 4006/4885TSHR 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.